Celltrion Inc. announced that Avtozma (tocilizumab-anoh) subcutaneous (SC) formulation is now available to patients in the United States. With this launch, Celltrion’s Avtozma becomes one of the first tocilizumab… read more.
Celltrion announced that the FDA has approved Avtozma (CT-P47, tocilizumab-anoh) in both an intravenous (IV) and subcutaneous (SC) formulation as a biosimilar to Actemra. Avtozma is indicated for… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
